Characterization of attenuated coxsackievirus B3 strains and prospects of their application as live-attenuated vaccines

Expert Opinion on Biological Therapy

Volumn 10, Issue 2, 2010, Pages 179-190

  Kim, Dae Sun ^a   Nam, Jae Hwan ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Attenuation; Coxsackievirus B3; Vaccine

Indexed keywords

COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; COXSACKIE VIRUS B3 VACCINE; LIVE VACCINE; PROTEIN VP1; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

CELLULAR IMMUNITY; COXSACKIE VIRUS B3; COXSACKIE VIRUS INFECTION; IMMUNE RESPONSE; NONHUMAN; PANCREATITIS; PHENOTYPE; PROTEIN MOTIF; REVIEW; VIRUS GENOME; VIRUS MUTANT; VIRUS MYOCARDITIS; VIRUS PATHOGENESIS; VIRUS VIRULENCE;

ANIMALS; ANTIBODIES, VIRAL; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS; GENETIC VECTORS; HUMANS; MUTATION; RECEPTORS, VIRUS; VACCINES, ATTENUATED;

COXSACKIEVIRUS;

EID: 76149097900     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590903379502     Document Type: Review

References (96)

1. Rueckert R. Picornaviridae: the viruses and their replication. In: Fields B, Knipe DM, eds. Virology. New York: Raven Press, 1996; 609-654
2. Pasch A, Frey FJ. Coxsackie B viruses and the kidney - a neglected topic. Nephrol Dial Transplant 2006;21:1184-1187
3. Henke A, Jarasch N, Martin U, et al. Recombinant coxsackievirus vectors for prevention and therapy of virus-induced heart disease. Int J Med. Microbiol 2008;298:127-134
4. Kim KS, Hufnagel G, Chapman NM, Tracy S. The group B coxsackieviruses and myocarditis. Rev Med. Virol 2001;11:355-368
5. O'Connell JB. The role of myocarditis in end-stage dilated cardiomyopathy. Tex Heart Inst J 1987;14:268-275
6. Sole MJ, Liu P. Viral myocarditis: a paradigm for understanding the pathogenesis and treatment of dilated cardiomyopathy. J Am Coll Cardiol 1993;22:99-105
7. Gillum RF. Idiopathic cardiomyopathy in the United States, 1970 - 1982. Am Heart J 1986;111:752-755
8. Whitton JL, Feuer R. Myocarditis, microbes and autoimmunity. Autoimmunity 2004;37:375-386
9. Martino T, liu P, Sole MJ. Enteroviral myocarditis and dilated cardiomyopathy: a review of clinical and experimental studies. In Human Enterovirus Infections, Robert H, ed. Washington,DC: ASM, 1995;291-351
10. Esfandiarei M, McManus BM. Molecular biology and pathogenesis of viral myocarditis. Annu Rev Pathol Mech Dis 2008;3:125-153
11. Lyden DC, Olszewski J, Feran M, et al. Coxsackievirus B-3-induced myocarditis. Effect of sex steroids on viremia and infectivity of cardiocytes. Am J Pathol 1987;126:432-438
12. Huber SA, Pfaeffle B. Differential Th1 and Th2 cell responses in male and female BALB/c mice infected with coxsackievirus group B type 3. J Virol 1994;68:5126-5132
13. Beck MA, Levander OA, Handy J. Selenium deficiency and viral infection. J Nutr 2003;133:S1463-7
14. Vasiljevic JD, Kanjuh V, Seferovic P, et al. The incidence of myocarditis in endomyocardial biopsy samples from patients with congestive heart failure. Am Heart J 1990;120:1370-1377
15. Aretz HT. Myocarditis: the Dallas criteria. Hum Pathol 1987;18:619-624
16. Paul AV, Van Boom JH, Filippov D, Wimmer E. Protein-primed RNA synthesis by purified poliovirus RNA polymerase. Nature 1998;393:280-284
17. Pelletier J, Sonenberg N. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature 1988;334:320-325
18. Dan M, Chantler JK. A genetically engineered attenuated coxsackievirus B3 strain protects mice against lethal infection. J Virol 2005;79:9285-9295
19. Knowlton KU, Jeon ES, Berkley N, et al. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectiouscDNAof the Woodruff variant of coxsackievirus B3. J Virol 1996;70:7811-7818
20. Stadnick E, Dan M, Sadeghi A, Chantler JK. Attenuating mutations in coxsackievirus B3 map to a conformational epitope that comprises the puff region of VP2 and the knob of VP3. J Virol 2004;78:13987-14002
21. Sherry B, Rueckert RR. Evidence for at least two dominant neutralization antigens on human rhinovirus 14. J Virol 1985;53:137-143
22. Minor PD, Ferguson M, Evans DM, et al. Antigenic structure of polioviruses of serotypes 1, 2, and 3. J Gen Virol 1986;67:1283-1291
23. Sherry B, Mosser AG, Colonno RJ, Rueckert RR. Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornaviruses of serotypes 1, 2, and 3. J Virol 1986;57:246-257
24. Chung SK, Kim JY, Kim IB, et al. Internalization and trafficking mechanisms of coxsackievirus B3 in HeLa cells. Virology 2005;333:31-40
25. Coyne CB, Bergelson JM. Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell 2006;124:119-131
26. Shi Y, Chen C, Lisewski U, et al. Cardiac deletion of the Coxsackievirus-adenovirus receptor abolishes Coxsackievirus B3 infection and prevents myocarditis in vivo. J Am Coll Cardiol 2009;53:1219-1226
27. Fairweather D, Yusung S, Frisancho S, et al. IL-12 receptor beta1 and Toll-like receptor 4 increase IL-1 beta- and IL-18-associated myocarditis and coxsackievirus replication. J Immunol 2003;170:4731-4737
28. Triantafilou K, Orthopoulos G, Vakakis E, et al.Human cardiac inflammatory responses triggered by Coxsackie B viruses are mainly Toll-like receptor (TLR) 8-dependent. Cell Microbiol 2005;7:1117-1126
29. Vella C, Festenstein H. Coxsackievirus B4 infection of the mouse pancreas: the role of natural killer cells in the control of virus replication and resistance to infection. J Gen Virol 1992;73:1379-1386
30. Huber S. T cells in coxsackievirus induced myocarditis. Viral Immunol 2004;17:152-164
31. Huber SA, Sartini D. Roles of tumor necrosis factor alpha (TNF-alpha) and the p55 TNF receptor in CD1d induction and coxsackievirus B3-induced myocarditis. J Virol 2005;79:2659-2665
32. Tam PE. Coxsackievirus myocarditis: Interplay between virus and host in the pathogenesis of heart disease. Viral Immunol 2006;19:133-146
33. Mena I, Perry CM, Harkin S, et al. The role of B lymphocytes in coxsackievirus B3 infection. Am J Pathol 1999;155:1205-1215
34. Opavsky MA, Penninger J, Aitken K, et al. Susceptibility to myocarditis is dependent on the response of alphabeta T lymphocytes to coxsackieviral infection. Circ Res 1999;85:551-558
35. Paque RE, Gauntt CJ, Nealon TJ. Assessment of cell-mediated immunity against coxsackievirus B3-induced myocarditis in a primate model (Papio papio). Infect Immun 1981;31:470-479
36. Fohlman J, Ilback NG, Friman G, Morein B. Vaccination of Balb/c mice against enteroviral mediated myocarditis. Vaccine 1990;8:381-384
37. Henke A, Jarasch N, Wutzler P. Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis. Expert Rev Vaccines 2008;7:1557-1567
38. FohlmanJ,PauksenK,MoreinB, et al.High yield production of an inactivated coxsackie B3 adjuvant vaccine with protective effect against experimental myocarditis. Scand J Infect Dis Suppl 1993;88:103-108
39. See DM, Tilles JG. Occurrence of coxsackievirus hepatitis in baby rabbits and protection by a formalin-inactivated polyvalent vaccine. Proc Soc Exp Biol Med 1997;21:52-56
40. Henke A, Wagner E, Whitton JL, et al. Protection of mice against lethal coxsackievirus B3 infection by using DNA immunization. J Virol 1998;72:8327-8331
41. Henke A, Zell R, Stelzner A. DNA vaccine-mediated immune responses in coxsackievirus B3-infected mice. Antiviral Res 2001;49:49-54
42. Kim JY, Jeon ES, Kim BK, et al. Immunogenicity of a DNA vaccine for coxsackievirus B3 in mice: protective effects of capsid proteins against viral challenge. Vaccine 2005;23:1672-1679
43. Xu W, Shen Y, Jiang Z, et al. Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection. Vaccine 2004;22:3603-3612
44. Hunziker IP, Harkins S, Feuer R, et al. Generation and analysis of a RNA vaccine that protects against coxsackievirus B3 challenge. Virology 2004;330:196-208
45. KimYJ,AhnJ, Jeung SY, et al. Recombinant lentivirus-delivered short hairpin RNAs targeted to conserved coxsackievirus sequences protect against viral myocarditis and improve survival rate in an animal model. Virus Genes 2008;36:141-146
46. Cambridge G, MacArthur CG, Waterson AP, et al. Antibodies to coxsackie B viruses in congestive cardiomyopathy. Br Heart J 1979;41:962-966
47. Wesselen L, Waldenstrom A, Lindblom B, et al. Genotypic and serotypic profile in dilated cardiomyopathy. Scand J Infect Dis 1993;88(Suppl):87-91
48. Park JH, Kim DS, Cho YJ, et al. Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis. Vaccine 2009;27:1974-1983
49. Bukreyev A, Belyakov IM. Expression of immunomodulating molecules by recombinant viruses: can the immunogenicity of live virus vaccines be improved? Expert Rev Vaccines 2002;1:233-245 (Pubitemid 36686873)
50. Trousdale MD, Paque RE, Gauntt CJ. Isolation of coxsackievirus B3 temperature-sensitive mutants and their assignment to complementation group. Biochem Biophys Res. Commun 1977;76:368-375
51. Gauntt CJ, Trousdale MD, Lee JC, Paque RE. Preliminary characterization of coxsackievirus B3 temperature-sensitive mutants. J Virol 1983;45:1037-1047
52. Trousdale MD, Paque RE, Nealon T, Gauntt CJ. Assessment of coxsackievirus B3 ts mutants for induction of myocarditis in a murine model. Infect Immun 1979;23:486-495
53. Gauntt CJ, Paque RE, Trousdale MD, et al. Temperature-sensitive mutant of coxsackievirus B3 establishes resistance in neonatal mice that protects them during adolescence against coxsackievirus B3-induced myocarditis. Infect Immun 1983;39:851-864
54. Godeny EK, Arizpe HM, Gauntt CJ. Characterization of the antibody response in vaccinated mice protected against coxsackievirus B3-induced myocarditis. Viral Immunol 1987/1988;1:305-314
55. Gauntt CJ, Trousdale MD, LaBadie DRL, et al. Properties of coxsackievirus B3 variants which are amyocarditic or myocarditic for mice. J Med. Virol 1979;3:207-220
56. Chapman NM, Tu Z, Tracy S, Gauntt CJ. An infectious cDNA copy of the genome of a non cardiovirulent coxsackievirus B3 strain: its complete sequence analysis and comparison to the genomes of cardiovirulent coxsackieviruses. Arch Virol 1994;135:115-130
57. Tu Z, Chapman NM, Hufnagel G, et al. The cardiovirulent phenotype of coxsackievirus B3 is determined at a single site in the genomic 5′ nontranslated region. J Virol 1995;69:4607-4618
58. Seo IS, Jee YM, Ahn JH. Mutation variants generated from nonvirulent coxsackievirus B3 acquire virulence phenotypes by active virus replication. Intervirology 2007;50:447-453
59. Chapman NM, Romero JR, Pallansch MA, Tracy S. Sites other than nucleotide 234 determine cardiovirulence in natural isolates of coxsackievirus B3. J Med. Virol 1997;52:258-261
60. Dunn JJ, Chapman NM, Tracy S, Romero JR. Genomic determinants of cardiovirulence in coxsackievirus B3 clinical isolates: localization to the 5′ nontranslated region. J Virol 2000;74:4787-4794
61. Dunn JJ, Bradrick SS, Chapman NM, et al. The stem loop II within the 5′ nontranslated region of clinical coxsackievirus B3 genomes determines cardiovirulence phenotype in a murine model. J Infect Dis 2003;187:1552-1561
62. Lee CK, Kono K, Haas E, et al. Characterization of an infectious cDNA copy of the genome of a naturally occurring, avirulent coxsackievirus B3 clinical isolate. J Gen Virol 2005;86:197-210
63. Zhang HY, Yousef GE, Cunningham L, et al. Attenuation of a reactivated cardiovirulent coxsackievirus B3: the 5′-nontranslated region does not contain major attenuation determinants. J Med. Virol 1993;41:129-137
64. Zhang H, Blake NW, Ouyang X, et al. A single amino acid substitution in the capsid protein VP1 of Coxsackievirus B3 (CVB3) alters plaque phenotype in Vero cells but not cardiovirulence in a mouse model. Arch Virol 1995;140:959-966
65. Cameron-Wilson CL, Pandolfino YA, Zhang HY, et al. Nucleotide sequence of an attenuated mutant of coxsackievirus B3 compared with the cardiovirulent wildtype: assessment of candidate mutations by analysis of a revertant to cardiovirulence. Clin Diagn Virol 1998;9:99-105
66. Zhang H, Morgan-Capner P, Latif N, et al. Coxsackievirus B3-induced myocarditis. Characterization of stable attenuated variants that protect against infection with the cardiovirulent wild-type strain. Am J Pathol 1997;150:2197-2207
67. Reagan KJ, Goldberg B, Crowell RL. Altered receptor specificity of Coxsackievirus B3 after growth in rhabdomyosarcoma cells. J Virol 1984;49:635-640
68. Landau BJ, Whittier PS, Finkelstein SD, et al. Induction of heterotypic virus resistance in adult inbred mice immunized with a variant of Coxsackievirus B3. Microb Pathog 1990;8:289-298
69. Bergelson JM, Mohanty JG, Crowell RL, et al. Coxsackievirus B3 adapted to growth in RD cells binds to decay-accelerating factor (CD55) J Virol 1995;69:1903-1906
70. Lindberg AM, Crowell RL, Zell R, et al. Mapping of the RD phenotype of the Nancy strain of coxsackievirus B3. Virus Res 1992;24:187-196
71. Van Houten N, Bouchard PE, Moraska A, Huber SA. Selection of an attenuated coxsackievirus B3 variant, using a monoclonal antibody reactive to myocyte antigen. J Virol 1991;65:1286-1290
72. + T-cell receptor. J Virol 1996;70:3039-3044
73. Huber SA, Feldman AM, Sartini D. Coxsackievirus B3 induces T regulatory cells, which inhibit cardiomyopathy in tumor necrosis factor-transgenic mice. Circ Res 2006;99:1109-1116
74. Huber SA, Moraska A, Choate M. T cells expressing the gammad T-cell receptor potentiate coxsackievirus B3-induced myocarditis. J Virol 1992;66:6541-6546
75. Yang D, Wilson JE, Anderson DR, et al. In vitro mutational and inhibitory analysis of the cis-acting translational elements within the 5′-untranslated region of coxsackievirus B3. Virology 1997;228:63-73
76. Liu Z, Carthy CM, Cheung P, et al. Structural and functional analysis of the 5′ untranslated region of coxsackievirus B3 RNA: in vivo translational and infectivity studies of full-length mutants. Virology 1999;265:206-217
77. M'hadheb-Gharbi MB, El Hiar R, Paulous S, et al. Role of GNRA motif mutations within stem-loop V of internal ribosome entry segment in coxsackievirus B3 molecular attenuation. J Mol Microbiol Biotechnol 2008;14:147-156
78. Malnou CE, Poyry TAA, Jackson RJ, KeanMK.Poliovirus internal ribosome entry segment structure alterations that specifically affect function in neuronal cells: molecular genetic analysis. J Virol 2002;76:10617-10626
79. Lanier LL. Viral immunoreceptor tyrosine-based activation motif (ITAM)-mediated signaling in cell transformation and cancer. Trends Cell Biol 2006;16:388-390
80. Girn J, Kavoosi M, Chantler J. Enhancementof coxsackievirusB3infection by antibody to a different coxsackievirus strain. J Gen Virol 2002;83:351-358
81. Jarasch N, Martin U, Zell R, et al. Influence of pan-caspase inhibitors on coxsackievirus B3-infected CD19+ B lymphocytes. Apoptosis 2007;12:1633-1643
82. Huisman W, Martina BEE, Rimmelzwaan GF, et al. Vaccine-induced enhancement of viral infections. Vaccine 2009;27:505-512
83. Nachman MW, Crowell SL. Estimate of the mutation rate per nucleotide in humans. Genetics 2000;156:297-304
84. Drake JW, Charlesworth B, Charlesworth D, Crow JF. Rates of spontaneous mutation. Genetics 1998;148:1667-1686
85. Kim KS, Tracy S, Tapprich W, et al. 5′-Terminal deletions occur in coxsackievirus B3 during replication in murine hearts and cardiac myocyte cultures and correlate with encapsidation of negative-strand viral RNA. J Virol 2005;79:7024-7041
86. Alvarez FL, Neu N, Rose NR, et al. Heart-specific autoantibodies induced by Coxsackievirus B3: identification of heart autoantigens. ClinImmunol Immunopathol 1987;43:129-139
87. Neu N, Beisel KW, Traystman MD, et al. Autoantibodies specific for the cardiac myosin isoform are found in mice susceptible to Coxsackievirus B3-induced myocarditis. J Immunol 1987;138:2488-2492
88. Beisel KW, Srinivasappa J, Olsen MR, et al. A neutralizing monoclonal antibody against Coxsackievirus B4 cross-reacts with contractile muscle proteins. Microb Pathog 1990;8:151-156
89. Henke A, Jarasch N, Wutzler P. Vaccination procedures against coxsackievirus-induced heart disease. Expert Rev Vaccines 2003;2:805-815
90. Chapman NM, Kim KS, Tracy S, et al. Coxsackievirus expression of the murine secretory protein interleukin-4 induces increased synthesis of immunoglobulin G1 in mice. J Virol 2000;74:7952-7962
91. Höfling K, Tracy S, Chapman N, et al. Expression of an antigenic adenovirus epitope in a group B coxsackievirus. J Virol 2000;74:4570-4578
92. Henke A, Zell R, Ehrlich G, Stelzner A. Expression of immunoregulatory cytokines by recombinant Coxsackievirus B3 variants confers protection against virus-induced myocarditis. J Virol 2001;75:8187-8194
93. Henke A, Zell R, Martin U, Stelzner A. Direct interferon-gamma-mediated protection caused by a recombinant coxsackievirus B3. Virology 2003;315:335-344
94. Suguitan AL Jr, McAuliffe J, Mills KL, et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 2006;3:1541-1555
95. Johnson PR, Feldman S, Thompson JM, et al. Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis 1986;154:121-127
96. van Ooij MJ, Vogt DA, Paul A, et al. Structural and functional characterization of the coxsackievirus B3 CRE(2C): role of CRE(2C) in negative- and positive-strand RNA synthesis. J Gen Virol 2006;87:103-113